KANSERDE OBEZİTEYE BAĞLI İNFLAMASYON

Authors

Rümeysa Özyurt

Synopsis

In this study, the negative effects of obesity-related chronic inflammation on cancer initiation, progression, and treatment are discussed. Defined as a body mass index of 30 or higher, obesity triggers low-grade chronic inflammation through pathophysiological processes such as insulin resistance, altered adipokine secretion, and macrophage infiltration in white adipose tissue. Hypertrophied adipocytes and macrophages in white adipose tissue increase the secretion of pro-inflammatory cytokines such as TNF-α, IL-1, and IL-6, while suppressing anti-inflammatory adiponectin levels. This inflammatory environment leads to lipid accumulation in lymphoid organs like the bone marrow and thymus, impairing hematopoiesis, shifting cell differentiation toward myeloid lineage, and reducing T-cell count and diversity, thereby weakening the immune system's ability to recognize tumor antigens. Prominent cancer types highlighted include postmenopausal and triple-negative breast cancer, colorectal cancer driven by gut dysbiosis and leptin/adiponectin imbalance, and liver cancer (HCC) associated with NAFLD and steatosis. Additionally, pancreatic, endometrial, ovarian, and esophageal cancers are linked to obesity. Consequently, biomarkers of adipose tissue inflammation play a critical role in identifying high-risk populations and developing novel therapeutic targets.

References

Guilherme A, Virbasius JV, Puri V, et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol, 2008; 9(5):367-377. doi:10.1038/nrm2391.

Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. Jama, 2014; 311(8):806-814. doi:10.1001/jama.2014.732.

Martin-Rodriguez E, Guillen-Grima F, Martí A, et al. Comorbidity associated with obesity in a large population: The APNA study. Obes Res Clin Pract, 2015; 9(5):435-447. doi:10.1016/j.orcp.2015.04.003.

Gholami M, Larijani B, Zahedi Z, et al. Inflammation related miRNAs as an important player between obesity and cancers. J Diabetes Metab Disord, 2019; 18(2):675-692. doi:10.1007/s40200-019-00459-2.

Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist, 2010; 15(6):556-565. doi:10.1634/theoncologist.2009-0285.

De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes, 2013; 2013:291546. doi:10.1155/2013/291546.

Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol, 2016; 29:77-89. doi:10.1016/j.coph.2016.07.005.

Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci, 2015; 36(7):461-470. doi:10.1016/j.tips.2015.04.014.

Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol, 2011; 29:415-445. doi:10.1146/annurev-immunol-031210-101322.

Solinas G, Karin M. JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. Faseb j, 2010; 24(8):2596-2611. doi:10.1096/fj.09-151340.

Nakamura T, Furuhashi M, Li P, et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell, 2010; 140(3):338-348. doi:10.1016/j.cell.2010.01.001.

Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm, 2010; 2010:802078. doi:10.1155/2010/802078.

Han JM, Levings MK. Immune regulation in obesity-associated adipose inflammation. J Immunol, 2013; 191(2):527-532. doi:10.4049/jimmunol.1301035.

Revelo XS, Tsai S, Lei H, et al. Perforin is a novel immune regulator of obesity-related insulin resistance. Diabetes, 2015; 64(1):90-103. doi:10.2337/db13-1524.

Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med, 2009; 15(8):914-920. doi:10.1038/nm.1964.

McLaughlin T, Liu LF, Lamendola C, et al. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol, 2014; 34(12):2637-2643. doi:10.1161/atvbaha.114.304636.

Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med, 2019; 25(3):477-486. doi:10.1038/s41591-018-0337-7.

Naaz A, Holsberger DR, Iwamoto GA, et al. Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity. Faseb j, 2004; 18(15):1925-1927. doi:10.1096/fj.04-2631fje.

Andersen CJ, Murphy KE, Fernandez ML. Impact of Obesity and Metabolic Syndrome on Immunity. Adv Nutr, 2016; 7(1):66-75. doi:10.3945/an.115.010207.

Szondy Z, Sarang Z, Kiss B, et al. Anti-inflammatory Mechanisms Triggered by Apoptotic Cells during Their Clearance. Front Immunol, 2017; 8:909. doi:10.3389/fimmu.2017.00909.

Quail DF, Dannenberg AJ. The obese adipose tissue microenvironment in cancer development and progression. Nat Rev Endocrinol, 2019; 15(3):139-154. doi:10.1038/s41574-018-0126-x.

Surmi BK, Hasty AH. Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidol, 2008; 3(5):545-556. doi:10.2217/17460875.3.5.545.

Ferrante AW, Jr. The immune cells in adipose tissue. Diabetes Obes Metab, 2013; 15 Suppl 3(0 3):34-38. doi:10.1111/dom.12154.

Woodall MJ, Neumann S, Campbell K, et al. The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy. Cancers, 2020; 12(5). doi:10.3390/cancers12051230.

Lee H, Lee IS, Choue R. Obesity, inflammation and diet. Pediatr Gastroenterol Hepatol Nutr, 2013; 16(3):143-152. doi:10.5223/pghn.2013.16.3.143.

Rakotoarivelo V, Lacraz G, Mayhue M, et al. Inflammatory Cytokine Profiles in Visceral and Subcutaneous Adipose Tissues of Obese Patients Undergoing Bariatric Surgery Reveal Lack of Correlation With Obesity or Diabetes. EBioMedicine, 2018; 30:237-247. doi:10.1016/j.ebiom.2018.03.004.

Sasi SP, Yan X, Enderling H, et al. Breaking the 'harmony' of TNF-α signaling for cancer treatment. Oncogene, 2012; 31(37):4117-4127. doi:10.1038/onc.2011.567.

Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat Immunol, 2012; 13(8):707-712. doi:10.1038/ni.2343.

Iwasaki H, Akashi K. Myeloid lineage commitment from the hematopoietic stem cell. Immunity, 2007; 26(6):726-740. doi:10.1016/j.immuni.2007.06.004.

Dixit VD. Impact of immune-metabolic interactions on age-related thymic demise and T cell senescence. Semin Immunol, 2012; 24(5):321-330. doi:10.1016/j.smim.2012.04.002.

Naveiras O, Nardi V, Wenzel PL, et al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature, 2009; 460(7252):259-263. doi:10.1038/nature08099.

Yang H, Youm YH, Vandanmagsar B, et al. Obesity accelerates thymic aging. Blood, 2009; 114(18):3803-3812. doi:10.1182/blood-2009-03-213595.

Healy LA, Ryan AM, Rowley S, et al. Obesity increases the risk of postmenopausal breast cancer and is associated with more advanced stage at presentation but no impact on survival. Breast J, 2010; 16(1):95-97. doi:10.1111/j.1524-4741.2009.00861.x.

Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol, 2014; 25(10):1901-1914. doi:10.1093/annonc/mdu042.

Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat, 2010; 123(3):627-635. doi:10.1007/s10549-010-0990-0.

Rose DP, Vona-Davis L. Influence of obesity on breast cancer receptor status and prognosis. Expert Rev Anticancer Ther, 2009; 9(8):1091-1101. doi:10.1586/era.09.71.

Bonsang-Kitzis H, Chaltier L, Belin L, et al. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy. PLoS One, 2015; 10(12):e0144359. doi:10.1371/journal.pone.0144359.

Osman MA, Hennessy BT. Obesity Correlation With Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast Cancer. Clin Med Insights Oncol, 2015; 9:105-112. doi:10.4137/cmo.S32812.

Sun X, Casbas-Hernandez P, Bigelow C, et al. Normal breast tissue of obese women is enriched for macrophage markers and macrophage-associated gene expression. Breast Cancer Res Treat, 2012; 131(3):1003-1012. doi:10.1007/s10549-011-1789-3.

Fuentes-Mattei E, Velazquez-Torres G, Phan L, et al. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. J Natl Cancer Inst, 2014; 106(7). doi:10.1093/jnci/dju158.

Picon-Ruiz M, Pan C, Drews-Elger K, et al. Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression. Cancer Res, 2016; 76(2):491-504. doi:10.1158/0008-5472.Can-15-0927.

Zhao Y, Nichols JE, Valdez R, et al. Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Mol Endocrinol, 1996; 10(11):1350-1357. doi:10.1210/mend.10.11.8923461.

Saxena NK, Sharma D. Multifaceted leptin network: the molecular connection between obesity and breast cancer. J Mammary Gland Biol Neoplasia, 2013; 18(3-4):309-320. doi:10.1007/s10911-013-9308-2.

Knüpfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat, 2007; 102(2):129-135. doi:10.1007/s10549-006-9328-3.

De Larco JE, Wuertz BR, Rosner KA, et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol, 2001; 158(2):639-646. doi:10.1016/s0002-9440(10)64005-9.

Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med, 2013; 64:45-57. doi:10.1146/annurev-med-121211-091527.

Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 2003; 348(17):1625-1638. doi:10.1056/NEJMoa021423.

Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health, 2009; 9:88. doi:10.1186/1471-2458-9-88.

Avgerinos KI, Spyrou N, Mantzoros CS, et al. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism, 2019; 92:121-135. doi:10.1016/j.metabol.2018.11.001.

Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. Bmj, 2017; 356:j477. doi:10.1136/bmj.j477.

Himbert C, Delphan M, Scherer D, et al. Signals from the Adipose Microenvironment and the Obesity-Cancer Link-A Systematic Review. Cancer Prev Res (Phila), 2017; 10(9):494-506. doi:10.1158/1940-6207.Capr-16-0322.

Sun A, Liu R, Sun G. Insulin therapy and risk of colorectal cancer: an updated meta-analysis of epidemiological studies. Curr Med Res Opin, 2014; 30(3):423-430. doi:10.1185/03007995.2013.858622.

Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond), 2008; 32(2):304-314. doi:10.1038/sj.ijo.0803713.

Rouet-Benzineb P, Aparicio T, Guilmeau S, et al. Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappaB signaling. J Biol Chem, 2004; 279(16):16495-16502. doi:10.1074/jbc.M312999200.

Tojek K, Anaszewicz M, Szukay B, et al. Circulating Leptin, Adiponectin, and Tumor Necrosis Factor-Alpha in Patients Undergoing Surgery Due to Colorectal Cancer. Digestion, 2021; 102(2):246-255. doi:10.1159/000504507.

Wang D, Chen J, Chen H, et al. Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J Biosci, 2012; 37(1):91-101. doi:10.1007/s12038-011-9172-4.

Moossavi S, Bishehsari F. Inflammation in sporadic colorectal cancer. Arch Iran Med, 2012; 15(3):166-170.

Liu Z, Brooks RS, Ciappio ED, et al. Diet-induced obesity elevates colonic TNF-α in mice and is accompanied by an activation of Wnt signaling: a mechanism for obesity-associated colorectal cancer. J Nutr Biochem, 2012; 23(10):1207-1213. doi:10.1016/j.jnutbio.2011.07.002.

Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol, 2014; 26(1):54-74. doi:10.1016/j.smim.2014.01.001.

Fazolini NP, Cruz AL, Werneck MB, et al. Leptin activation of mTOR pathway in intestinal epithelial cell triggers lipid droplet formation, cytokine production and increased cell proliferation. Cell Cycle, 2015; 14(16):2667-2676. doi:10.1080/15384101.2015.1041684.

Sugiyama M, Takahashi H, Hosono K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol, 2009; 34(2):339-344.

Lukanova A, Söderberg S, Kaaks R, et al. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 2006; 15(2):401-402. doi:10.1158/1055-9965.Epi-05-0836.

Grivennikov SI, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature, 2012; 491(7423):254-258. doi:10.1038/nature11465.

Puppa MJ, White JP, Sato S, et al. Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. Biochim Biophys Acta, 2011; 1812(12):1601-1606. doi:10.1016/j.bbadis.2011.08.010.

Pfalzer AC, Nesbeth PD, Parnell LD, et al. Diet- and Genetically-Induced Obesity Differentially Affect the Fecal Microbiome and Metabolome in Apc1638N Mice. PLoS One, 2015; 10(8):e0135758. doi:10.1371/journal.pone.0135758.

Schulz MD, Atay C, Heringer J, et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. Nature, 2014; 514(7523):508-512. doi:10.1038/nature13398.

Gurses SA, Banskar S, Stewart C, et al. Nod2 protects mice from inflammation and obesity-dependent liver cancer. Sci Rep, 2020; 10(1):20519. doi:10.1038/s41598-020-77463-7.

Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol, 2017; 8(6):429-436. doi:10.5306/wjco.v8.i6.429.

Han ZG. Functional genomic studies: insights into the pathogenesis of liver cancer. Annu Rev Genomics Hum Genet, 2012; 13:171-205. doi:10.1146/annurev-genom-090711-163752.

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 2012; 142(7):1592-1609. doi:10.1053/j.gastro.2012.04.001.

Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism, 2016; 65(8):1080-1086. doi:10.1016/j.metabol.2015.11.008.

Woo Baidal JA, Lavine JE. The intersection of nonalcoholic fatty liver disease and obesity. Sci Transl Med, 2016; 8(323):323rv321. doi:10.1126/scitranslmed.aad8390.

Larsson S, Wolk A. Overweight, obesity and risk of liver cancer: A meta-analysis of cohort studies. British Journal of Cancer, 2007; 97:1005-1008. doi:10.1038/sj.bjc.6603932.

Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol, 2012; 56(3):704-713. doi:10.1016/j.jhep.2011.09.020.

Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology, 2010; 52(2):774-788. doi:10.1002/hep.23719.

Nakagawa H, Umemura A, Taniguchi K, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell, 2014; 26(3):331-343. doi:10.1016/j.ccr.2014.07.001.

Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 2010; 140(2):197-208. doi:10.1016/j.cell.2009.12.052.

Jiang N, Sun R, Sun Q. Leptin signaling molecular actions and drug target in hepatocellular carcinoma. Drug Des Devel Ther, 2014; 8:2295-2302. doi:10.2147/dddt.S69004.

Kim J, Guan KL. Regulation of the autophagy initiating kinase ULK1 by nutrients: roles of mTORC1 and AMPK. Cell Cycle, 2011; 10(9):1337-1338. doi:10.4161/cc.10.9.15291.

White E, Karp C, Strohecker AM, et al. Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol, 2010; 22(2):212-217. doi:10.1016/j.ceb.2009.12.008.

Mima K, Baba H. The gut microbiome, antitumor immunity, and liver cancer. Hepatobiliary Surg Nutr, 2019; 8(1):67-68. doi:10.21037/hbsn.2018.11.09.

Majumder K, Gupta A, Arora N, et al. Premorbid Obesity and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2016; 14(3):355-368.e; quiz e332. doi:10.1016/j.cgh.2015.09.036.

Teper Y, Eibl G. Pancreatic Macrophages: Critical Players in Obesity-Promoted Pancreatic Cancer. Cancers, 2020; 12(7). doi:10.3390/cancers12071946.

Cox AD, Olive KP. Silencing the killers: paracrine immune suppression in pancreatic cancer. Cancer Cell, 2012; 21(6):715-716. doi:10.1016/j.ccr.2012.05.029.

Zeng X, Xie YJ, Liu YT, et al. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta, 2020; 502:214-221. doi:10.1016/j.cca.2019.11.003.

Foong KW, Bolton H. Obesity and ovarian cancer risk: A systematic review. Post Reprod Health, 2017; 23(4):183-198. doi:10.1177/2053369117709225.

McDonald ME, Bender DP. Endometrial Cancer: Obesity, Genetics, and Targeted Agents. Obstet Gynecol Clin North Am, 2019; 46(1):89-105. doi:10.1016/j.ogc.2018.09.006.

Gu W, Chen C, Zhao KN. Obesity-associated endometrial and cervical cancers. Front Biosci (Elite Ed), 2013; 5:109-118. doi:10.2741/e600.

Sardana RK, Chhikara N, Tanwar B, et al. Dietary impact on esophageal cancer in humans: a review. Food Funct, 2018; 9(4):1967-1977. doi:10.1039/c7fo01908d.

Published

May 11, 2021

License

License